An analysis is presented of the histopathologic, clinical and prognostic features of malignant lymphomas (MLs) treated at the University of the Philippines-Philippine General Hospital Medical Center, Manila, between 1975 and 1981. There were 434 malignant lymphomas, constituting 3.86% of all cancers studied at this institute during this period. Non-Hodgkin's lymphomas accounted for 82%. Among these, nodular lymphomas constituted 8% of the group and diffuse lymphomas 92%. In diffuse lymphomas, poorly differentiated lymphocytic lymphomas (31%) and histiocytic lymphomas (30%) were predominant. Pleomorphic lymphomas, which are frequently observed in southwestern Japan and are now known to be a peculiar type of adult T-cell lymphoma/leukemia, were not found in this group. Hodgkin's disease constituted 18% of all the malignant lymphomas, among which there were 52% mixed cellular type and 21% lymphocytic depletion type. These data were correlated with those of other countries.
Download full-text PDF |
Source |
---|
JAMA Oncol
January 2025
Division of Pediatric Hematology, Oncology and Bone Marrow Transplantation, Cleveland Clinic Pediatric Institute, Cleveland, Ohio.
JAMA Oncol
January 2025
Children's Wisconsin, Milwaukee.
Importance: Retrieval strategies for children, adolescents, and young adults with relapsed classic Hodgkin lymphoma (cHL) aim to maintain efficacy while minimizing long-term toxic effects. Children, adolescents, and young adults with low-risk, relapsed cHL may benefit from replacing high-dose chemotherapy and autologous stem cell transplant with less intensive involved-site radiotherapy (ISRT).
Objective: To evaluate a risk-stratified, response-adapted, transplant-free approach for treatment of children, adolescents, and young adults with low-risk relapsed cHL with nivolumab plus brentuximab vedotin (BV) followed by BV plus bendamustine for patients with suboptimal response and ISRT (30.
JAMA Oncol
January 2025
Department of Pediatric Oncology, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia.
JAMA Oncol
January 2025
Department of Paediatric Haematology, Oncology and Immunodeficiency, University Hospital Justus-Liebig University Giessen, Giessen, Germany.
Importance: The current standard-of-care salvage therapy in relapsed/refractory classic Hodgkin lymphoma (cHL) includes consolidation high-dose chemotherapy (HDCT)/autologous stem cell transplant (aSCT).
Objective: To investigate whether presalvage risk factors and fludeoxyglucose-18 (FDG) positron emission tomography (PET) response to reinduction chemotherapy can guide escalation or de-escalation between HDCT/aSCT or transplant-free consolidation with radiotherapy to minimize toxic effects while maintaining high cure rates.
Design, Setting, And Participants: EuroNet-PHL-R1 was a nonrandomized clinical trial that enrolled patients younger than 18 years with first relapsed/refractory cHL across 68 sites in 13 countries in Europe between January 2007 and January 2013.
Indian J Pediatr
January 2025
Division of Pediatric Oncology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, 110029, India.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!